{"nctId":"NCT00129220","briefTitle":"Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder","startDateStruct":{"date":"2005-07"},"conditions":["Bipolar Disorder"],"count":224,"armGroups":[{"label":"Olanzapine","type":"EXPERIMENTAL","interventionNames":["Drug: olanzapine"]},{"label":"Haloperidol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: haloperidol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"olanzapine","otherNames":["LY170053","Zyprexa"]},{"name":"haloperidol","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meet the criteria for manic or mixed episodes according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) and have a diagnosis of \"294.4x Bipolar I Disorder, Most Recent Episode Manic\" or \"296.6x Bipolar I Disorder, Most Recent Episode Mixed\".\n* Have a total score on the Young Mania Rating Scale (YMRS) of at least 20 at Visit 1 and Visit 2.\n\nExclusion Criteria:\n\n* Have received an antidepressant or a psychostimulant within 5 days prior to Visit 1.\n* The duration of the current episode is more than 90 days at Visit 1.\n* Have a history or a diagnosis of diabetes mellitus.\n* Have received any psychotropic medication within 2 days prior to Visit 2 (except for benzodiazepines).","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score","description":"The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.6","spread":"10.0"},{"groupId":"OG001","value":"-14.3","spread":"11.4"},{"groupId":"OG002","value":"-6.8","spread":"14.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 6 Week Endpoint in Young Mania Rating Scale (YMRS)","description":"The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","spread":"11.4"},{"groupId":"OG001","value":"-14.7","spread":"13.1"},{"groupId":"OG002","value":"-10.1","spread":"15.8"}]}]}]},{"type":"SECONDARY","title":"Remission Rate of Bipolar Disorder (Olanzapine Versus Haloperidol)","description":"Remission of bipolar disorder was defined as completing the 6-week period with meeting the criteria for Young Mania Rating Scale (YMRS) total score of 12 or less and 17-Item Hamilton Depression Rating Scale (HAMD-17) total scores of 7 or less at Week 6. YMRS is an 11-item scale measuring severity of manic episodes; total score ranges = 0 (normal) to 60 (severe). The 17-item HAMD measures depression severity; total score ranges = 0 (normal) to 52 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 6 Week Endpoint in Clinical Global Impressions - Bipolar Version (CGI-BP), Overall Severity of Illness","description":"A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of overall mood symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.5"},{"groupId":"OG001","value":"-1.3","spread":"1.8"},{"groupId":"OG002","value":"-0.9","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 3 Week and 6 Week Endpoints in Clinical Global Impression - Bipolar Version (CGI-BP) Mania Subscale","description":"A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of manic symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.2"},{"groupId":"OG001","value":"-1.7","spread":"1.7"},{"groupId":"OG002","value":"-0.6","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"1.5"},{"groupId":"OG001","value":"-1.9","spread":"1.9"},{"groupId":"OG002","value":"-1.0","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Response Rate of Manic Symptoms at 3 Weeks and 6 Weeks","description":"Participants who had 50 percent or more decrease from the baseline in YMRS total scores were defined as a responder. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. Response Rate (percent) = number of patients meeting response criterion for manic symptom divided by number of patients in treatment arm, multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"65.0","spread":null},{"groupId":"OG002","value":"44.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.3","spread":null},{"groupId":"OG001","value":"65.0","spread":null},{"groupId":"OG002","value":"55.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission Rate of Manic Symptoms at 3 Weeks and 6 Weeks","description":"Participants who had a YMRS total score of 12 or less were considered to be in remission of manic symptoms. YMRS is an 11-item scale that measures severity of manic episodes; total score ranges from 0 (normal) to 60 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":null},{"groupId":"OG001","value":"65.0","spread":null},{"groupId":"OG002","value":"41.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"52.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Switched to Symptomatic Depression","description":"Switch to symptomatic depression was defined as HAMD-17 total score ≥13 at any time in the participants with HAMD-17 total scores ≤7 at baseline. The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 3 Week and 6 Week Endpoints in the Positive Subscore of Positive and Negative Syndrome Scale (PANSS)","description":"Assesses positive symptoms associated with schizophrenia. 7 items make up the Positive scale (ex. delusions, conceptual disorganization, and hallucinatory behavior). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Positive Subscale scores range from 7 to 49. For this study, the score was converted to 0 to 6 for each item range; hence, the total positive subscale score ranges from 0 to 42.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"4.1"},{"groupId":"OG001","value":"-1.8","spread":"4.3"},{"groupId":"OG002","value":"-0.0","spread":"5.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"4.4"},{"groupId":"OG001","value":"-1.6","spread":"4.3"},{"groupId":"OG002","value":"-0.3","spread":"5.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Switched to Syndromic Depression","description":"Switch to syndromic depression was operationally defined by meeting both of the following criteria: At baseline, the symptoms did not meet the criteria for a mixed episode based on the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR). The critiera were met for a Major Depressive Episode (MDE), at any point after randomization, based on DSM-IV-TR. Rather than the 2-week period required for an MDE in the DSM-IV-TR, the patient had to meet the criteria of an MDE for at least 7 consecutive days (during Weeks 1 through 6).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"5.3","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"5.3","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Change From Baseline During 6-Week Period in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Total Score","description":"Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.66"},{"groupId":"OG001","value":"0.50","spread":"1.19"},{"groupId":"OG002","value":"0.30","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"1.51"},{"groupId":"OG001","value":"2.70","spread":"2.89"},{"groupId":"OG002","value":"0.09","spread":"1.09"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":105},"commonTop":["Somnolence","Nasopharyngitis","Thirst","Constipation","Weight increased"]}}}